NASDAQ · Biotechnology

MCRB (MCRB) Stock

$5.54 +6.95% NASDAQ: MCRB Healthcare

Valuation

MetricValue
Price$5.54
Market Cap$53.65M
P/E Ratio11.97
P/B Ratio1.69
P/S Ratio64.67
EPS (TTM)$0.64
52-Week High$29.98
52-Week Low$4.34
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE13.64%
ROA4.35%
ROCE-213.64%
Gross Margin-9400.00%
Operating Margin-9400.00%
Net Margin-40.89%
Debt/Equity3.04
Current Ratio2.58

Annual Financials (USD)

Metric20212022202320242025
Revenue$145.0M$0$0$0$1.0M
Operating Profit$-64.0M$-180.0M$-195.0M$-121.0M$-94.0M
Net Profit$-66.0M$-250.0M$-114.0M$-147.0M$6.0M
EPS$-14.30$-46.29$-17.77$-18.86$0.64
Op Margin-44.5%———-11910.1%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$355.0M$349.0M$359.0M$140.0M$138.0M
Total Liabilities$223.0M$338.0M$403.0M$126.0M$94.0M
Cash$180.0M$163.0M$128.0M$31.0M$46.0M
Borrowings$49.0M$163.0M$199.0M$92.0M$83.0M

Latest News

Seres Therapeutics’ SER-155 Posts 80% Response in Cancer Immunotherapy GI Toxicity Study MarketBeat · Jul 10, 2026 Sector Update: Healthcare Stocks Lean Lower Pre-Bell Wednesday MT Newswires · Jul 8, 2026 Seres Therapeutics' Phase 1 Trial of SER-155 Meets Primary Endpoint; Shares Rise Pre-Bell MT Newswires · Jul 8, 2026 Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment GlobeNewswire · Jul 8, 2026 Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis GlobeNewswire · Jun 25, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$7.0M$-229.0M$-117.0M$-149.0M$1.0M
Investing Cash Flow$55.0M$73.0M$3.0M$142.0M$0
Financing Cash Flow$2.0M$3.0M$3.0M$14.0M$0
Net Cash Flow$72.0M$-17.0M$-35.0M$-97.0M$15.0M
Free Cash Flow$-3.0M$-239.0M$-125.0M$-149.0M$1.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-57.12%
Quick Ratio1.65
Interest Coverage—
Return 1Y-62.92%
Return 3Y-93.98%
Return 5Y-98.69%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ABOS $3.10 +6.16% -1.17 $223.91M 0.00%
ACTU $1.30 -15.58% -1.46 $31.10M 0.00%
APLTApplied Therapeutics, Inc. $0.10 +0.00% -0.24 $14.86M 0.00%
CGTX $1.05 +3.96% -3.94 $93.97M 0.00%
HURA $2.09 +2.96% -3.75 $133.10M 0.00%

About MCRB

MCRB is led by CEO Richard N. Kender, employs 103 people, headquartered in US, publicly traded since 2015.

MCRB stock trades at $5.54 with a market capitalization of $53.65M. The stock is valued at a price-to-earnings (P/E) ratio of 11.97, price-to-book of 1.69, price-to-sales of 64.67. Over the past 52 weeks the stock has ranged between $4.34 and $29.98, and currently trades 81.5% below its 52-week high.

On profitability, MCRB generates a return on equity (ROE) of 13.64%, above the typical market average, return on capital employed of -213.64%, an operating margin of -9400.00%, a net profit margin of -40.89%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1160.06 +0.01% JNJ Drug Manufacturers - General $275.21 +1.48% ABBV Drug Manufacturers - General $261.70 +0.66% MRK Drug Manufacturers - General $151.64 +1.19% UNH Medical - Healthcare Plans $399.66 +0.85% NVS Drug Manufacturers - General $162.46 +0.75% AZN Drug Manufacturers - General $161.63 -0.52% AMGN Drug Manufacturers - General $442.84 +1.08% TMO Medical - Diagnostics & Research $608.54 +1.34% NVO Biotechnology $46.77 +3.66% ABT Medical - Devices $110.49 +1.43% GILD Drug Manufacturers - General $149.61 -0.21%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides